Trial
NCT01777256
An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Systemic Lupus Erythematosus
Intervention
GSK2586184 50 mg
Why stopped
This study met a protocol defined futility criterion and will be terminated following completion of the Follow Up Visit on the last subject randomised.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-04-26